Hongfu Cai

11PUBLICATIONS
7CO-AUTHORS
Predictive and prognostic markersMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 01, 2025
Cost-effectiveness of sequential treatment strategies involving first-line pembrolizumab with trastuzumab and chemotherapy for unresectable metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Caicong You, Jiahao Zhang, Jianying Lei

|Aug 04, 2025
Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States.

Caicong You, Jiahao Zhang, Jianying Lei

|Dec 18, 2024
Cost-effectiveness of nivolumab combined with chemotherapy as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma.

Jingwen Lin, Xiaobing Song, Wu Fu

|Nov 29, 2023
Cemiplimab combined with chemotherapy <i>versus</i> chemotherapy in advanced non-small cell lung cancer: an updated EMPOWER-Lung 3 trial-based cost-effectiveness analysis.

Gaofeng Zhu, Hongfu Cai, Zhiwei Zheng

|May 24, 2023
First-line nivolumab plus chemotherapy <i>versus</i> chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis.

Xueqiong Cao, Mingming Zhang, Na Li

|Nov 08, 2022
Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis.

Liu Yang, Zhiwei Zheng, Na Li

Pageof 2

Frequent Collaborators

3 joint publications

Maobai Liu

2 joint publications

Zhiwei Zheng

2 joint publications

Jiahao Zhang

2 joint publications

Jianying Lei